sintilimab sintilimab sintilimab, sold under the brand tyvyt among others, is a medication used to treat hodgkin's disease, and has been approved in china. sintilimabmonoclonal antibodytype?clinical dataother namesanti-pd-1 monoclonal antibody ibi308identifierscas number2072873-06-2unii8fu7fq8upkkeggd12119 it is a fully human igg4 monoclonal antibody that binds to programmed cell death protein 1. it was jointly developed by innovent biologics and eli lilly. medical uses sintilimab is medication that is indicated for the treatment of relapsed or refractory classical hodgkin's lymphoma after failure of at least second-line systemic chemotherapy. side effects common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation. research currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors. in january 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical hodgkin's lymphoma was published.